Mr. Blacher has served as Chief Financial Officer since July 2022. Previously, Mr. Blacher helped build and manage Teva Pharmaceutical’s corporate VC portfolio of 25 life sciences companies, where he was directly responsible for licensing and investing activities for Teva’s early-stage innovative pipeline that spanned development stages ranging from pre-clinical through Phase III and multiple therapeutic areas, including neurology, auto-immune and oncology. Following Teva, Mr. Blacher served as CFO/CBO to 3 NASDAQ-listed biopharma companies, where he architected and executed wide-ranging financial transactions, including IPOs, follow-on offerings, licensing and partnerships, in addition to establishing and augmenting finance/accounting functions, including FP&A, audit, tax, cash management, SEC reporting and compliance, and investor relations. Earlier in his career, Mr. Blacher served in positions of increasing responsibility in the investment management and corporate finance industry as an equity analyst at Deutsche Asset Management (buy-side), Morgan Stanley (sell-side) and Lehman Brothers (investment banking). Mr. Blacher received an MBA in finance from Columbia Business School and a BA in economics from Yeshiva University.